Basics Corbus Pharmaceuticals Holdings, Inc. Common Stock Corbus Pharmaceuticals Holdings Inc is a Phase 3 clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. IPO Date: November 1, 2014 Sector: Healthcare Industry: Biotech Market Cap: $120.84M Activated in VL: True Average Daily Range Avg Daily Range: $0.31 | 3.88% Avg Daily Range (30 D): $0.25 | 2.61% Avg Daily Range (90 D): $0.26 | 3.19% Institutional Daily Volume Avg Daily Volume: 1.27M Avg Daily Volume (30 D): .09M Avg Daily Volume (90 D): .11M Trade Size Avg Trade Size (Sh.): 251 Avg Trade Size (Sh.) (30 D): 76 Avg Trade Size (Sh.) (90 D): 66 Institutional Trades Total Inst.Trades: 436 Avg Inst. Trade: $1.78M Avg Inst. Trade (30 D): $.77M Avg Inst. Trade (90 D): $2.32M Avg Inst. Trade Volume: .04M Avg Inst. Trades (Per Day): 1 Market Closing Trades Avg Closing Trade: $2.08M Avg Closing Trade (30 D): $6.62M Avg Closing Trade (90 D): $6.62M Avg Closing Volume: 44.19K     News Jul 10, 2025 @ 5:00 PM Cannabinoid Agonist Clinical Trial Pipeline Appear... Source: Delveinsight May 22, 2025 @ 12:00 PM Corbus Pharmaceuticals to Present at the Jefferies... Source: N/A Jun 1, 2024 @ 2:00 PM SYS6002 (CRB-701) A Next-Generation Nectin-4 Targe... Source: Corbus Pharmaceuticals Holdings, Inc. May 23, 2024 @ 9:05 PM Updated Phase 1 Clinical Data for SYS-6002 (CRB-70... Source: Corbus Pharmaceuticals Holdings, Inc. May 14, 2024 @ 5:32 PM Will Pharma And Healthcare Have Competitive Edge I... Source: Nicolás Jose Rodriguez Financials   TTM Q2 2025 Q1 2025 Basic EPS $-4.74 $-1.44 $-1.39 Diluted EPS $-4.74 $-1.44 $-1.39 Revenue $ 7.74M $ 1.31M $ 1.68M Gross Profit $ $ $ Net Income / Loss $ -57.95M $ -17.66M $ -16.98M Operating Income / Loss $ -67.04M $ -19.15M $ -19.78M Cost of Revenue $ $ $ Net Cash Flow $ -6.49M $ M $ M PE Ratio     Splits Feb 14, 2023:   1:30